X
FDA says Clovis’ Rubraca could be prostate cancer breakthrough
https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
Clovis
AZ’s Lynparza becomes first PARP drug approved in breast cancer
Lynparza first in class approved in breast cancer
Clovis PARP drug gets fast US review in new ovarian cancer use
Impressed by survival data, FDA hastens review in expanded patient group
Tesaro’s Zejula primed for EU approval, battle with AZ
EU regulators recommend PARP inhibitor Zejula
Rubraca outshines rivals in ovarian cancer maintenance therapy
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
Clovis and BMS combine cancer drugs in late-stage trials
Clovis and BMS research small molecule and antibody combination.
Clovis looks for new drugs after Rubraca success
US biotech looks to bolster pipeline.
Tesaro’s niraparib approved in ovarian cancer
Company nabs maintenance therapy use, but problems on breast cancer trial.
AZ’s Lynparza impresses with new ovarian cancer data
UK firm lays down the gauntlet in the PARP inhibitor battle.
1 2
